Cytogel Pharma, a biopharmaceutical development company based in Darien, Connecticut, announced on Friday that it Alan W. Dunton, MD has been appointed to its board.
Dunton has devoted his 35-year career to the discovery and development of new prescription and OTC drug products. He has been CEO/COO of both public and private biotechnology companies and was the president and managing director of the Janssen Research Foundation – the R&D and Regulatory arm of the pharmaceuticals division at Johnson and Johnson. He has also been at Roche, Syntex, Novartis (as CIBA-GEIGY) and Purdue.
C. Dean Maglaris, CEO of Cytogel Pharma, stated: "Dr. Dunton brings a depth and breadth of experience and leadership throughout his accomplished career in the pharmaceutical industry and will add significant value to the development of the Company's compounds for moderate to severe pain, starting with CYT-1010. He has worked at the highest level of research and development and has brought many products through full development, including drugs for the treatment of pain."
Bioforum, The Data Masters names new President
VolitionRx names new Chief Medical Officer
Quotient Sciences announces new appointments
Syndax Pharmaceuticals names new chief commercial officer
Everest Medicines names new chief medical officer and chief product officer
D3 Bio names new independent board member
Rigel Pharmaceuticals names new executive vice president and chief medical officer
Telix Pharmaceuticals names new group chief operating officer